387 related articles for article (PubMed ID: 30305503)
1. [State-of-the-art treatment of acute promyelocytic leukemia].
Kiguchi T
Rinsho Ketsueki; 2018; 59(10):2007-2018. PubMed ID: 30305503
[TBL] [Abstract][Full Text] [Related]
2. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
3. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
4. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
5. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
[TBL] [Abstract][Full Text] [Related]
6. [Therapies for newly diagnosed acute promyelocytic leukemia].
Yokoyama Y
Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
[TBL] [Abstract][Full Text] [Related]
7. [Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].
Creutzig U; Dworzak M; von Neuhoff N; Rasche M; Reinhardt D
Klin Padiatr; 2018 Oct; 230(6):299-304. PubMed ID: 30399642
[TBL] [Abstract][Full Text] [Related]
8. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
9. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Ohnishi K
Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
12. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
13. Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system.
Nagai S; Takahashi T; Kurokawa M
CNS Neurol Disord Drug Targets; 2009 Nov; 8(5):387-92. PubMed ID: 19702568
[TBL] [Abstract][Full Text] [Related]
14. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Tsimberidou AM; Estey E; Whitman GJ; Dryden MJ; Ratnam S; Pierce S; Faderl S; Giles F; Kantarjian HM; Garcia-Manero G
Leuk Res; 2004 Sep; 28(9):991-4. PubMed ID: 15234578
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).
Lancet JE; Moseley AB; Coutre SE; DeAngelo DJ; Othus M; Tallman MS; Litzow MR; Komrokji RS; Erba HP; Appelbaum FR
Blood Adv; 2020 Apr; 4(8):1683-1689. PubMed ID: 32330241
[TBL] [Abstract][Full Text] [Related]
16. Role of arsenic trioxide in acute promyelocytic leukemia.
Iland HJ; Seymour JF
Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117
[TBL] [Abstract][Full Text] [Related]
17. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.
Tobita T; Takeshita A; Kitamura K; Ohnishi K; Yanagi M; Hiraoka A; Karasuno T; Takeuchi M; Miyawaki S; Ueda R; Naoe T; Ohno R
Blood; 1997 Aug; 90(3):967-73. PubMed ID: 9242525
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
Sasaki K; Ravandi F; Kadia T; DiNardo CD; Yilmaz M; Short N; Jabbour E; Patel KP; Loghavi S; Pierce S; Borthakur G; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):375-381. PubMed ID: 38431521
[TBL] [Abstract][Full Text] [Related]
20. The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.
Nagai S; Takahashi T; Kurokawa M
Curr Stem Cell Res Ther; 2010 Dec; 5(4):372-8. PubMed ID: 20528759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]